Бізнес · 17.07.20201 хв читання
Eli Lilly and Co.; Announcement of the Revocation of the Biologics License for LARTRUVO
Локальний автоматичний переклад · Оригінальна мова джерела
Короткий зміст
The Food and Drug Administration (FDA or Agency) is announcing the revocation of the biologics license application (BLA) for LARTRUVO (olaratumab) injection. Eli Lilly and Co. requested withdrawal (revocation) of the biologics license application and has waived its opportunity for a hearing.